Optimizing the Choice for Adjuvant Chemotherapy in Gastric Cancer
Advances in the management of gastric cancer have improved patient survival in the last decade. Nonetheless, the number of patients relapsing and dying after a diagnosis of localized gastric cancer is still too high, even in early stages (10% in stage I). Adjuvant systemic chemotherapy has been prov...
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-09-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/14/19/4670 |
| _version_ | 1797480283087306752 |
|---|---|
| author | Antonino Grassadonia Antonella De Luca Erminia Carletti Patrizia Vici Francesca Sofia Di Lisa Lorena Filomeno Giuseppe Cicero Laura De Lellis Serena Veschi Rosalba Florio Davide Brocco Saverio Alberti Alessandro Cama Nicola Tinari |
| author_facet | Antonino Grassadonia Antonella De Luca Erminia Carletti Patrizia Vici Francesca Sofia Di Lisa Lorena Filomeno Giuseppe Cicero Laura De Lellis Serena Veschi Rosalba Florio Davide Brocco Saverio Alberti Alessandro Cama Nicola Tinari |
| author_sort | Antonino Grassadonia |
| collection | DOAJ |
| description | Advances in the management of gastric cancer have improved patient survival in the last decade. Nonetheless, the number of patients relapsing and dying after a diagnosis of localized gastric cancer is still too high, even in early stages (10% in stage I). Adjuvant systemic chemotherapy has been proven to significantly improve outcomes. In the present article we have critically reviewed the clinical trials that guide the current clinical practice in the adjuvant treatment of patients affected by resectable gastric cancer, focusing on the different approaches worldwide, i.e., adjuvant chemotherapy, adjuvant chemoradiotherapy, and perioperative chemotherapy. We also delineate the clinical–pathological characteristics that are commonly taken into account to identify patients at a higher risk of recurrence and requiring adjuvant chemotherapy, and also describe novel biomarkers and therapeutic agents that might allow personalization of the treatment. |
| first_indexed | 2024-03-09T21:57:49Z |
| format | Article |
| id | doaj.art-8761e680f40c4c6eb71c1b37dc1578be |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-09T21:57:49Z |
| publishDate | 2022-09-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-8761e680f40c4c6eb71c1b37dc1578be2023-11-23T19:54:38ZengMDPI AGCancers2072-66942022-09-011419467010.3390/cancers14194670Optimizing the Choice for Adjuvant Chemotherapy in Gastric CancerAntonino Grassadonia0Antonella De Luca1Erminia Carletti2Patrizia Vici3Francesca Sofia Di Lisa4Lorena Filomeno5Giuseppe Cicero6Laura De Lellis7Serena Veschi8Rosalba Florio9Davide Brocco10Saverio Alberti11Alessandro Cama12Nicola Tinari13Department of Innovative Technologies in Medicine and Dentistry, and Center for Advanced Studies and Technology (CAST), G. D’Annunzio University Chieti-Pescara, 66100 Chieti, ItalyDepartment of Medical, Oral and Biotechnological Sciences, and Center for Advanced Studies and Technology (CAST), G. D’Annunzio University Chieti-Pescara, 66100 Chieti, ItalyDepartment of Medical, Oral and Biotechnological Sciences, and Center for Advanced Studies and Technology (CAST), G. D’Annunzio University Chieti-Pescara, 66100 Chieti, ItalyUnit of Phase IV Trials, IRCCS Regina Elena National Cancer Institute, 00144 Rome, ItalyUnit of Phase IV Trials, IRCCS Regina Elena National Cancer Institute, 00144 Rome, ItalyUnit of Phase IV Trials, IRCCS Regina Elena National Cancer Institute, 00144 Rome, ItalyDepartment of Surgical, Oncological and Oral Sciences, Section of Medical Oncology, University of Palermo, 90133 Palermo, ItalyDepartment of Pharmacy, G. D’Annunzio University Chieti-Pescara, 66100 Chieti, ItalyDepartment of Pharmacy, G. D’Annunzio University Chieti-Pescara, 66100 Chieti, ItalyDepartment of Pharmacy, G. D’Annunzio University Chieti-Pescara, 66100 Chieti, ItalyDepartment of Pharmacy, G. D’Annunzio University Chieti-Pescara, 66100 Chieti, ItalyUnit of Medical Genetics, Department of Biomedical Sciences—BIOMORF, University of Messina, 98125 Messina, ItalyDepartment of Pharmacy, G. D’Annunzio University Chieti-Pescara, 66100 Chieti, ItalyDepartment of Medical, Oral and Biotechnological Sciences, and Center for Advanced Studies and Technology (CAST), G. D’Annunzio University Chieti-Pescara, 66100 Chieti, ItalyAdvances in the management of gastric cancer have improved patient survival in the last decade. Nonetheless, the number of patients relapsing and dying after a diagnosis of localized gastric cancer is still too high, even in early stages (10% in stage I). Adjuvant systemic chemotherapy has been proven to significantly improve outcomes. In the present article we have critically reviewed the clinical trials that guide the current clinical practice in the adjuvant treatment of patients affected by resectable gastric cancer, focusing on the different approaches worldwide, i.e., adjuvant chemotherapy, adjuvant chemoradiotherapy, and perioperative chemotherapy. We also delineate the clinical–pathological characteristics that are commonly taken into account to identify patients at a higher risk of recurrence and requiring adjuvant chemotherapy, and also describe novel biomarkers and therapeutic agents that might allow personalization of the treatment.https://www.mdpi.com/2072-6694/14/19/4670gastric canceradjuvant chemotherapypredictive factorsprognostic factors |
| spellingShingle | Antonino Grassadonia Antonella De Luca Erminia Carletti Patrizia Vici Francesca Sofia Di Lisa Lorena Filomeno Giuseppe Cicero Laura De Lellis Serena Veschi Rosalba Florio Davide Brocco Saverio Alberti Alessandro Cama Nicola Tinari Optimizing the Choice for Adjuvant Chemotherapy in Gastric Cancer Cancers gastric cancer adjuvant chemotherapy predictive factors prognostic factors |
| title | Optimizing the Choice for Adjuvant Chemotherapy in Gastric Cancer |
| title_full | Optimizing the Choice for Adjuvant Chemotherapy in Gastric Cancer |
| title_fullStr | Optimizing the Choice for Adjuvant Chemotherapy in Gastric Cancer |
| title_full_unstemmed | Optimizing the Choice for Adjuvant Chemotherapy in Gastric Cancer |
| title_short | Optimizing the Choice for Adjuvant Chemotherapy in Gastric Cancer |
| title_sort | optimizing the choice for adjuvant chemotherapy in gastric cancer |
| topic | gastric cancer adjuvant chemotherapy predictive factors prognostic factors |
| url | https://www.mdpi.com/2072-6694/14/19/4670 |
| work_keys_str_mv | AT antoninograssadonia optimizingthechoiceforadjuvantchemotherapyingastriccancer AT antonelladeluca optimizingthechoiceforadjuvantchemotherapyingastriccancer AT erminiacarletti optimizingthechoiceforadjuvantchemotherapyingastriccancer AT patriziavici optimizingthechoiceforadjuvantchemotherapyingastriccancer AT francescasofiadilisa optimizingthechoiceforadjuvantchemotherapyingastriccancer AT lorenafilomeno optimizingthechoiceforadjuvantchemotherapyingastriccancer AT giuseppecicero optimizingthechoiceforadjuvantchemotherapyingastriccancer AT lauradelellis optimizingthechoiceforadjuvantchemotherapyingastriccancer AT serenaveschi optimizingthechoiceforadjuvantchemotherapyingastriccancer AT rosalbaflorio optimizingthechoiceforadjuvantchemotherapyingastriccancer AT davidebrocco optimizingthechoiceforadjuvantchemotherapyingastriccancer AT saverioalberti optimizingthechoiceforadjuvantchemotherapyingastriccancer AT alessandrocama optimizingthechoiceforadjuvantchemotherapyingastriccancer AT nicolatinari optimizingthechoiceforadjuvantchemotherapyingastriccancer |